Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oe
Read time: 1 mins
Last updated:23rd Sep 2010
Effect on progression free survival defined as the time measured from the day of registration to first progression or death.
|Study start date||2010-09-23|